Cardiology

How to prevent recurrent stroke when the cause is unknown

Nearly one-third of patients with a stroke of unknown cause have a heart rhythm disorder that can be treated to prevent another stroke. That's the finding of the NOR-FIB study presented at EHRA 2022, a scientific congress ...

Cardiology

Results from the COBRA-REDUCE trial reported

For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding ...

Cardiology

Results from the OAC-ALONE trial reported

The first randomized trial of its kind was unable to establish non-inferiority of oral anticoagulation (OAC) alone to combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation (AF) and stable ...

Cardiology

New guidance on antithrombotic use in AF patients with ACS

A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome ...

Cardiology

Omission of aspirin from antiplatelet regimen: The WOEST study

Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and ...

Cardiology

Von Willebrand factor linked to bleeding complications

(HealthDay) -- Oral anticoagulation (OAC)-treated patients with high levels of von Willebrand factor (VWF) have elevated risks of bleeding complications and cardiovascular and all-cause mortality, according to a study published ...

page 5 from 5